Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial
Mark T. Gladwin, Victor R. Gordeuk, Payal Desai, Caterina P. Minniti, Enrico M. Novelli, Claudia R. Morris, Kenneth I. Ataga, Laura Castro, Susanna A. Curtis, Fuad El Rassi, H. James Ford, Thomas J. Harrington, Elizabeth S. Klings, Sophie Lanzkron, Darla Liles, Jane A. Little, Alecia Nero, Wally R. Smith, James G. Taylor, Ayanna Baptiste, Ward Hagar, Julie Kanter, Amy Kinzie, Temeia Martin, Amina Rafique, Marilyn J. Telen, Christina M. Lalama, Gregory J. Kato, Kaleab Z. Abebe
Topics & Concepts
MedicineRiociguatPlaceboProteinuriaInternal medicineSickle cell anemiaDiseaseClinical trialAnemiaGastroenterologyPulmonary hypertensionKidneyPathologyAlternative medicineChronic thromboembolic pulmonary hypertensionHemoglobinopathies and Related DisordersErythropoietin and Anemia TreatmentPulmonary Hypertension Research and Treatments